|
Mar 13
|
HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid
|
|
Mar 13
|
HLS Therapeutics Appoints Christine Elliott to its Board of Directors
|
|
Feb 21
|
Positive Signs As Multiple Insiders Buy HLS Therapeutics Stock
|
|
Jul 29
|
HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan
|
|
Jul 25
|
HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call
|
|
May 28
|
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment
|
|
Apr 9
|
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
|
|
Apr 8
|
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
|
|
Dec 5
|
HLS Therapeutics (TSE:HLS) shareholders have endured a 78% loss from investing in the stock three years ago
|
|
Nov 9
|
HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid
|
|
Aug 14
|
HLS Therapeutics Announces Updates to its Credit Agreement
|
|
Aug 10
|
HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results
|
|
May 3
|
HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference Call
|